<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339245</url>
  </required_header>
  <id_info>
    <org_study_id>PHO-0956</org_study_id>
    <nct_id>NCT03339245</nct_id>
  </id_info>
  <brief_title>Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study</brief_title>
  <official_title>Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function&#xD;
      tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver&#xD;
      disease. Fructose ingestion by the American public has steadily increased since the 1980's,&#xD;
      and with it increases in NAFLD, fatty liver hepatitis (NASH), diabetes, obesity, and&#xD;
      cardiovascular disease. Foods and beverage in the U.S. are typically sweetened with sucrose&#xD;
      (50% glucose and 50% fructose) or high fructose corn syrup (45-58% glucose and 42-55%&#xD;
      fructose) (Stanhope, et al., 2009). Research into the role that added fructose plays in the&#xD;
      emerging chronic health issues is necessary to affect public policy and provide the&#xD;
      connection between fructose and the increasing incidence of these co-morbidities.&#xD;
&#xD;
      There is evidence that gut bacteria contribute to a range of human diseases including those&#xD;
      of the liver and gastrointestinal tract. Dietary fructose has been suggested to play a role&#xD;
      in the development of these diseases and has been shown to alter gut microbes in animals. If&#xD;
      the investigators find that dietary fructose alters bacteria in the human gut, this would&#xD;
      suggest a potential targetable link between high fructose diet and disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non- alcoholic fatty liver disease (NAFLD) occurs in 30% of the adult US population (Luther,&#xD;
      J., et al., 2015). Eating large amounts of fructose (a dietary sugar) increases liver fat&#xD;
      accumulation and worsens NAFLD. In addition, fructose consumption has been shown to greatly&#xD;
      increase triglycerides(fat) in the blood after meals, increasing the risk of heart&#xD;
      disease,(Stanhope,et al., 2009) insulin resistance and diabetes. Current theories on liver&#xD;
      disease caused by consuming fructose focuses on changes in the breakdown of fat by the liver.&#xD;
      In experimental animals, fructose feeding changes the bacteria population (microbiota) in the&#xD;
      gut, causes NAFLD and NASH, and increases leaking of toxins from the intestine (intestinal&#xD;
      permeability) to the blood stream resulting in inflammation.&#xD;
&#xD;
      In humans, fructose consumption rapidly increases liver fat. However, changes in gut&#xD;
      microbiota have not been studied. The proposed study will compare the addition of fructose or&#xD;
      glucose to the study subjects' usual diet in a crossover design. They will not know which&#xD;
      sugar they are receiving.&#xD;
&#xD;
      The Investigators plan to study postmenopausal, moderately obese but healthy women, and&#xD;
      moderately obese but healthy men (age 45-70 years) to find out the effect of fructose verses&#xD;
      glucose on the bacteria in their stool and inflammation in the bowel. The Investigators&#xD;
      hypothesize that adding fructose to the participant's usual diet, compared to glucose, will&#xD;
      change stool bacteria composition and the products that the bacteria produce, which may&#xD;
      increase intestinal leakage, and increase markers of inflammation in the stool and blood due&#xD;
      to this leakage. These changes may contribute to fructose -induced liver disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Actual">October 2, 2018</completion_date>
  <primary_completion_date type="Actual">October 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the Distribution of Fecal Microbiota in Each Participant</measure>
    <time_frame>assessed at Day 16 of each intervention, up to 64 days</time_frame>
    <description>Difference in the distribution of fecal microbiota in each participant, between the fructose versus glucose supplemented diet arms of the study, as measured at the end of each intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Glucose, Then Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose, Then Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fructose Solution (75 Grams)</intervention_name>
    <description>Fructose given in divided doses at breakfast and dinner.</description>
    <arm_group_label>Fructose, Then Glucose</arm_group_label>
    <arm_group_label>Glucose, Then Fructose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose Solution (75 grams)</intervention_name>
    <description>Glucose given in divided doses at breakfast and dinner.</description>
    <arm_group_label>Fructose, Then Glucose</arm_group_label>
    <arm_group_label>Glucose, Then Fructose</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post menopausal female, last menstrual period at least 24 months ago OR male&#xD;
&#xD;
          -  Age 45-70&#xD;
&#xD;
          -  Willing to consume usual diet with either fructose or glucose added during (2) 16-18&#xD;
             day inpatient stays&#xD;
&#xD;
          -  Willing to consume usual diet during 2 week wash-out period at home&#xD;
&#xD;
          -  BMI 30.0-39.9&#xD;
&#xD;
          -  Willingness not to travel long distances while on study, including wash-out period&#xD;
&#xD;
          -  Willingness not to be exposed to new pets while on study including wash-out period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting serum triglycerides &gt;200mg/dl&#xD;
&#xD;
          -  Fasting blood glucose &gt;126mg/dl&#xD;
&#xD;
          -  Renal function tests &gt;2x Upper limit of normal&#xD;
&#xD;
          -  Liver Function Tests &gt; 1.5x Upper limit of normal&#xD;
&#xD;
          -  Currently on statins&#xD;
&#xD;
          -  Daily use of a cathartic&#xD;
&#xD;
          -  Broad spectrum antibiotic use within the past 45 days&#xD;
&#xD;
          -  Currently on proton pump inhibitor&#xD;
&#xD;
          -  Currently on insulin or oral hypoglycemic agents&#xD;
&#xD;
          -  Active viral Hepatitis&#xD;
&#xD;
          -  Chronic constipation&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  GI resection&#xD;
&#xD;
          -  Any evidence of cardiovascular disease on EKG&#xD;
&#xD;
          -  History of cardiovascular disease such as coronary artery disease, Coronary Artery&#xD;
             Bypass Graft, valve replacement, Myocardial Infarction, stroke / Transient Ischemic&#xD;
             attack.&#xD;
&#xD;
          -  History of macronutrient malabsorption&#xD;
&#xD;
          -  Current smoker. Stopped &lt; 3 months ago.&#xD;
&#xD;
          -  Daily alcohol intake equal to 1.5 oz of 40 proof alcohol.&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Any medical, psychological or social condition that, in the opinion of the&#xD;
             Investigator, would jeopardize the health or well-being of the participant during any&#xD;
             study procedures or the integrity of the data&#xD;
&#xD;
          -  Persons taking probiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Holt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004 Dec;40(6):1387-95.</citation>
    <PMID>15565570</PMID>
  </reference>
  <reference>
    <citation>Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, Deshpande V, Singh G, Turner JR, Yarmush ML, Chung RT, Patel SJ. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.</citation>
    <PMID>26405687</PMID>
  </reference>
  <reference>
    <citation>Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009 May;119(5):1322-34. doi: 10.1172/JCI37385. Epub 2009 Apr 20.</citation>
    <PMID>19381015</PMID>
  </reference>
  <reference>
    <citation>Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.</citation>
    <PMID>26600078</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>fructose</keyword>
  <keyword>glucose</keyword>
  <keyword>fecal microbiota</keyword>
  <keyword>intestinal permiability</keyword>
  <keyword>fecal metabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03339245/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fructose, Then Glucose</title>
          <description>Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
        </group>
        <group group_id="P2">
          <title>Glucose, Then Fructose</title>
          <description>Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">1 withdrawn due to elevated glucose during pre-intervention testing&#xD;
1 withdrawn for personal reason</participants>
                <participants group_id="P2" count="6">1 withdrawn due to elevated glucose on baseline testing</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Glucose to Fructose group, 1 was withdrawn due to A/E Total evaluated = 6 Fructose to Glucose group: 1 was withdrawn due to A/E, 1 due to personal reason Total evaluated = 4</population>
      <group_list>
        <group group_id="B1">
          <title>Glucose, Then Fructose</title>
          <description>Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
        </group>
        <group group_id="B2">
          <title>Fructose, Then Glucose</title>
          <description>Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>The row population indicates the N in each arm. This is a cross-over study, so each participant received the same intervention but in different order</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="50" upper_limit="67"/>
                    <measurement group_id="B2" value="57" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="B3" value="57.6" lower_limit="50" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in the Distribution of Fecal Microbiota in Each Participant</title>
        <description>Difference in the distribution of fecal microbiota in each participant, between the fructose versus glucose supplemented diet arms of the study, as measured at the end of each intervention.</description>
        <time_frame>assessed at Day 16 of each intervention, up to 64 days</time_frame>
        <population>Investigator has retired and access to results for each arm was not available for this outcome. Best efforts were made to obtain the data from the investigator; however, they were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose, Then Glucose</title>
            <description>Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
          </group>
          <group group_id="O2">
            <title>Glucose, Then Fructose</title>
            <description>Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Distribution of Fecal Microbiota in Each Participant</title>
          <description>Difference in the distribution of fecal microbiota in each participant, between the fructose versus glucose supplemented diet arms of the study, as measured at the end of each intervention.</description>
          <population>Investigator has retired and access to results for each arm was not available for this outcome. Best efforts were made to obtain the data from the investigator; however, they were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <desc>Adverse event data are reported per arm/group. Adverse event per intervention are not available because the Investigator has retired. Best efforts were made to obtain and reexamine the adverse event data; however, they were unsuccessful.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fructose, Then Glucose</title>
          <description>Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
        </group>
        <group group_id="E2">
          <title>Glucose, Then Fructose</title>
          <description>Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.&#xD;
Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner.&#xD;
Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>mild nausea resolved spontaneously</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>elevated blood glucose</sub_title>
                <description>fasting glucose &gt;125mg/dl</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>low back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>low back pain after excercising</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>lightheadedness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>mild lightheadedness after drinking study sugar, resolved spontaneously</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter R Holt</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7706</phone>
      <email>holtp@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

